Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Seltorexant with Midazolam and Warfarin
NCT02617810Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of seltorexant in major depressive disorder (MDD) and Insomnia, sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) of Midazolam at Day 7, Area Under the Plasma Concentration-Time Curve (AUC) of Midazolam at Day 7 and 6 more. Started Nov 2015; status: completed.
02
Drugs
seltorexant
03
Conditions
major depressive disorder (MDD)Insomnia
Beyond the preview
Go deeper on NCT02617810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617810.